Skip to content

Hypnosis and Attention in Patients With a Neurological Disease (Stroke, Traumatic Brain Injury and Multiple Sclerosis)

Hypnosis and Attention in Patients With a Neurological Disease

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07256704
Acronym
HYPNOVA
Enrollment
48
Registered
2025-12-01
Start date
2025-11-18
Completion date
2029-07-31
Last updated
2026-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis, Stroke, Traumatic Brain Injury

Keywords

Hypnosis, Attention deficit, Neurorehabilitation, Electroencephalography (EEG)

Brief summary

This feasibility study investigates the potential of hypnosis as a complementary therapy for improving attentional deficits and reducing fatigue in patients with neurological conditions such as stroke, traumatic brain injury (TBI), and multiple sclerosis (MS). These patients often experience reduced spontaneous visual exploration and impaired functional independence despite current rehabilitation approaches. By integrating hypnosis with standard care and using EEG to monitor brain activity during hypnosis and sham-hypnosis sessions, this trial aims to evaluate the feasibility, acceptability, and preliminary efficacy of hypnosis in enhancing attention and reducing fatigue.

Detailed description

Neurological conditions such as stroke, traumatic brain injury (TBI), and multiple sclerosis (MS) frequently cause significant impairments in attentional abilities. Commonly accompanying symptoms include visual spatial neglect (VSN) and fatigue syndrome, which exacerbate attentional deficits. These impairments manifest notably as a reduction in spontaneous or free visual exploration (FVE), limiting patients' ability to actively scan and engage with their environment. This diminished visual exploration negatively impacts their capacity to navigate daily surroundings, compromising functional independence and overall quality of life. Current therapeutic approaches include cognitive rehabilitation, visual exploration training, and non-invasive brain stimulation to promote neuroplasticity and functional recovery. Additionally, management of fatigue focuses on energy regulation strategies in everyday life. Despite these interventions, many patients continue to experience persistent attentional deficits and fatigue after rehabilitation, limiting their ability to perform daily activities and return to previous roles. Hypnosis is emerging as a promising adjunct therapy in neurological rehabilitation. Widely used in medical fields such as pain management and mental health, hypnosis leverages the brain's ability to enter a state of focused attention and heightened cognitive receptivity, facilitating symptom relief and treatment enhancement without pharmacological side effects. Preliminary evidence suggests hypnosis can improve attentional control and reduce fatigue in neurological populations. However, research on hypnosis in neurology remains limited, with a need for larger, rigorously controlled studies to confirm its efficacy and understand underlying mechanisms. This feasibility study aims to assess the practicality and acceptability of using hypnosis to treat attentional deficits and fatigue in patients with stroke, TBI, and MS, while also evaluating preliminary efficacy. A key aspect of this study involves recording electroencephalography (EEG) during both hypnosis and sham-hypnosis sessions. EEG data will provide insight into neural correlates of attentional processing and determine whether hypnosis induces measurable changes in brain activity relative to sham conditions.

Interventions

OTHERIntervention Hypnosis

Hypnosis sessions designed to improve attentional control and reduce fatigue in patients with neurological conditions (stroke, TBI, MS). The intervention involves guided hypnotic induction and suggestions tailored to enhance cognitive focus and energy management.

Sponsors

Luzerner Kantonsspital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

This study is a double-blind design, where both participants and outcome assessors are blinded to the intervention assignment. Participants will not know whether they are receiving hypnosis or sham hypnosis, minimizing expectancy and placebo effects. Outcome assessors who conduct attentional testing will also be blinded to group allocation to reduce assessment bias. Due to the nature of the intervention, the practitioner administering the sessions may be aware of the condition but will have no role in outcome assessment.

Intervention model description

Participants are randomly assigned to one of two groups: the hypnosis intervention group or the sham hypnosis control group. Arm 1: Hypnosis Intervention Description: Participants receive hypnosis sessions designed to improve attention and reduce fatigue. Arm 2: Sham Hypnosis Control Description: Participants receive sham hypnosis sessions serving as a control condition.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* ICD-10 Diagnosis of stroke, TBI or MS * Admitted to the inpatient and/or outpatient in the Clinic for Neurology and Neurorehabilitation * Age 18 years old or older * Understanding the German language * Written informed consent

Exclusion criteria

\- Psychiatric disease

Design outcomes

Primary

MeasureTime frameDescription
Feasibility of the study design and proceduresFrom enrollment to the end of treatment at 3 weeksThe primary objective is to evaluate the feasiblity of conducting the study by assessing the completion rate.

Secondary

MeasureTime frameDescription
Video-oculography during free visual explorationChange before and after the intervention over the period of 3 weeks.The secondary endpoint is change in eye movement parameters during free visual exploration (FVE) from pre- to post-intervention, measured by video-oculography (mean gaze positions measured in °). Furthermore, between-group differences (hypnosis vs sham-hypnosis) in FVE parameters post-intervention.

Countries

Switzerland

Contacts

CONTACTThomas Nyffeler, Prof. Dr. med.
thomas.nyffeler@luks.ch+41412055686

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 15, 2026